Category: Press Releases

Paradigm Therapeutics Acquires Late Stage “Breakthrough Therapy” Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB)

‘Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface’ MT PLEASANT, S.C., Aug. 22, 2023 — Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of the worldwide rights of SD-101, a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB), from Amicus Therapeutics. Terms of the deal […]

Paradigm Therapeutics logo - Partner in Rare Diseases

Copyright © 2024 Paradigm Therapeutics. All Rights Reserved.


Website by  Creare Web Solutions